Bank of America
PHAT icon

Bank of America’s Phathom Pharmaceuticals PHAT Stock Holding History

Bank of America’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Sell
151,015
-57,100
-27% -$652K ﹤0.01% 4343
2026
Q1 		$2.31M Sell
208,115
-50,881
-20% -$643K ﹤0.01% 4023
2025
Q4 		$4.3M Buy
258,996
+9,902
+4% +$141K ﹤0.01% 3508
2025
Q3 		$2.93M Buy
249,094
+153,014
+159% +$1.58M ﹤0.01% 4489
2025
Q2 		$921K Sell
96,080
-74,201
-44% -$411K ﹤0.01% 5348
2025
Q1 		$1.07M Buy
170,281
+3,776
+2% +$22.9K ﹤0.01% 5169
2024
Q4 		$1.35M Buy
166,505
+62,726
+60% +$777K ﹤0.01% 4777
2024
Q3 		$1.88M Buy
103,779
+5,747
+6% +$80.3K ﹤0.01% 4611
2024
Q2 		$1.01M Sell
98,032
-7,823
-7% -$80.6K ﹤0.01% 4901
2024
Q1 		$1.12M Buy
105,855
+24,062
+29% +$204K ﹤0.01% 4864
2023
Q4 		$747K Buy
81,793
+28,235
+53% +$243K ﹤0.01% 5208
2023
Q3 		$555K Sell
53,558
-2,524
-5% -$34.6K ﹤0.01% 5248
2023
Q2 		$803K Sell
56,082
-197,403
-78% -$2.28M ﹤0.01% 4934
2023
Q1 		$1.81M Buy
253,485
+188,023
+287% +$1.65M ﹤0.01% 4440
2022
Q4 		$734K Sell
65,462
-5,286
-7% -$54.5K ﹤0.01% 5094
2022
Q3 		$784K Sell
70,748
-20,796
-23% -$198K ﹤0.01% 5062
2022
Q2 		$772K Buy
91,544
+24,884
+37% +$256K ﹤0.01% 5119
2022
Q1 		$908K Sell
66,660
-7,731
-10% -$125K ﹤0.01% 5368
2021
Q4 		$1.46M Buy
74,391
+9,857
+15% +$232K ﹤0.01% 4875
2021
Q3 		$2.07M Buy
64,534
+990
+2% +$32.9K ﹤0.01% 4407
2021
Q2 		$2.15M Sell
63,544
-1,460
-2% -$52.3K ﹤0.01% 4260
2021
Q1 		$2.44M Buy
65,004
+25,025
+63% +$1.05M ﹤0.01% 4086
2020
Q4 		$1.33M Buy
39,979
+34,945
+694% +$1.42M ﹤0.01% 4271
2020
Q3 		$184K Buy
5,034
+479
+11% +$16.6K ﹤0.01% 5347
2020
Q2 		$150K Sell
4,555
-11,188
-71% -$430K ﹤0.01% 5442
2020
Q1 		$406K Buy
15,743
+13,888
+749% +$464K ﹤0.01% 4651
2019
Q4 		$58K Buy
+1,855
New +$46.6K ﹤0.01% 6214

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bank of America's PHAT Position: Q2 2026 in Review

Bank of America reduced its Phathom Pharmaceuticals (PHAT) stake by 27% in Q2 2026, selling an estimated $652K and leaving 151,015 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #4343.

Bank of America first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $4.3M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Bank of America held 151,015 shares of Phathom Pharmaceuticals worth $1.64M as of Q2 2026.
  • Bank of America sold 57,100 Phathom Pharmaceuticals shares in Q2 2026, an estimated $652K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #4343 holding.
  • Bank of America first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Bank of America's Phathom Pharmaceuticals position peaked at $4.3M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.